About the Authors
- Marta Garcia-Montojo
-
* E-mail: mgarciamon.hcsc@salud.madrid.org
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- María Dominguez-Mozo
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- Ana Arias-Leal
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- Ángel Garcia-Martinez
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- Virginia De las Heras
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- Ignacio Casanova
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- Raphaël Faucard
-
Affiliation Geneuro Innovation, Lyon, France
- Nadège Gehin
-
Affiliation Geneuro Innovation, Lyon, France
- Alexandra Madeira
-
Affiliation Geneuro Innovation, Lyon, France
- Rafael Arroyo
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- François Curtin
-
Affiliation Geneuro Innovation, Lyon, France
- Roberto Alvarez-Lafuente
-
Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
- Hervé Perron
-
Affiliation Geneuro Innovation, Lyon, France
Competing Interests
RF, NG, AM, FC and HP are employees of Geneuro and MGM received honoraria from this company for scientific consultancy. The study has been funded in part by Geneuro Innovation, a company developing therapies and diagnostic tools for diseases associated with the expression of human endogenous retroviruses, with a primary focus on the Nervous System diseases and Multiple Sclerosis. There are no patents, further products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MGM FC HP RAL. Performed the experiments: MGM AAL AGM MDM. Analyzed the data: MGM RAL HP VDH IC RA. Contributed reagents/materials/analysis tools: RF NG AM. Wrote the paper: MGM RAL HP.